Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhythm BiosciencesFRA:0RY +11.11%31 Debt-to-Equity is 0.12 as of Dec. 2025, which is 300% above its 10-year median of 0.03. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Rhythm Biosciences ranks better than 69.4% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rhythm Biosciences's Debt-to-Equity or its related term are showing as below:
FRA:0RY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 1.68
Current: 0.12
During the past 8 years, the highest Debt-to-Equity Ratio of Rhythm Biosciences was 1.68. The lowest was 0.00. And the median was 0.03.
FRA:0RY's Debt-to-Equity is ranked better than 69.4% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.31
vs FRA:0RY: 0.12
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Rhythm Biosciences Debt-to-Equity Related Terms
Rhythm Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0RY vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Rhythm Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Biosciences (FRA:0RY) has a Debt-to-Equity of 0.12 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rhythm Biosciences and its competitors. This is 300% above median its historical median of 0.03. According to the industry distribution chart, Rhythm Biosciences ranks #56 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 30.6%.
Is Rhythm Biosciences' Debt-to-Equity too high?
Rhythm Biosciences' current Debt-to-Equity of 0.12 is 300% above median its 10-year median of 0.03. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.31. Rhythm Biosciences' value of 0.12 is 61.3% below this industry median. Based on the distribution chart, Rhythm Biosciences ranks #56 out of 183 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #56 out of 183 companies for Debt-to-Equity. This puts Rhythm Biosciences in the upper half of its industry. The industry median Debt-to-Equity is 0.31. Rhythm Biosciences' value of 0.12 is 61.3% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.31, Rhythm Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.31, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Biosciences's current Debt-to-Equity of 0.12 is 61.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current Debt-to-Equity is 0.12, which is 300% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Debt-to-Equity of 0.12. The current Debt-to-Equity is 0.12, which is 300% above median its 10-year median of 0.03 and 61.3% below the Medical Diagnostics & Research industry median of 0.31. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Debt-to-Equity is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score
Get the complete analysis for FRA:0RY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0RY has been successfully added to your 
